Clinical Trials
245 trialsGEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Genmab
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
M.D. Anderson Cancer Center
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Pfizer
CPIT001
Hackensack Meridian Health
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
Hackensack Meridian Health
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
iinnovate-3
Teva Branded Pharmaceutical Products R&D, Inc.
iinnovate-1
Teva Branded Pharmaceutical Products R&D, Inc.
iinnovate-2
Teva Branded Pharmaceutical Products R&D, Inc.
TOMMY
Institut Cancerologie de l'Ouest
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
Incyte Corporation
LIMBER
Incyte Corporation
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Mayo Clinic
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
Scripps Translational Science Institute
PROACT
Washington University School of Medicine
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
Amgen
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Ipsen
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Thomas Jefferson University
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Cartesian Therapeutics
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Thomas Jefferson University
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Gilead Sciences
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
University of Maryland, Baltimore
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
Janssen Research & Development, LLC
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
Celgene
Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy
Roswell Park Cancer Institute
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM
GlaxoSmithKline
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
Hackensack Meridian Health
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
Takeda
EMBRACE
Medical College of Wisconsin
Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients
Wake Forest University Health Sciences
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
University of California, San Francisco
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
Seagen Inc.
T-cell Receptor α/β Depleted Donor Lymphocyte Infusion
Baptist Health South Florida
Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Cartesian Therapeutics
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
Altor BioScience
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Columbia University
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
Jazz Pharmaceuticals
Precision Medicine for Patients With Identified Actionable Mutations
Wake Forest University Health Sciences
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Altor BioScience
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
University of California, San Francisco
SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Stemline Therapeutics, Inc.
P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
Poseida Therapeutics, Inc.
Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
University of Nebraska
Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
GlaxoSmithKline
OCEAN
Oncopeptides AB